Home Research funding AcureX Therapeutics Receives Grant from Michael J. Fox Foundation for Parkinson’s Disease...

AcureX Therapeutics Receives Grant from Michael J. Fox Foundation for Parkinson’s Disease Research

4
0

SAN CARLOS, Calif., April 27, 2022–(BUSINESS WIRE)–AcureX Therapeutics Corporation, a private, preclinical-stage biopharmaceutical company focused on developing potential disease-modifying therapies for neurodegenerative diseases, today announced that it has been selected to receive a grant from the Michael J. Fox Foundation to accelerate development of AcureX’s biomarker for use in Parkinson’s disease drug development and clinical trials.

Parkinson’s disease (PD) is a debilitating neurodegenerative disease characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. The causes of PD are largely unknown and under intense investigation. However, a large body of evidence now supports that mitophagy, the normal process by which cells shed dysfunctional mitochondria, plays an important and early role in the pathogenesis of Parkinson’s disease. AcureX co-founder Professor Xinnan Wang of the Department of Neurosurgery at Stanford University discovered that the mitochondrial protein Miro1 functions as a privileged gatekeeper controlling the onset of mitophagy. Additionally, Miro1 fails to degrade, leading to mitophagy defects in patients with genetic and sporadic forms of PD. Recent studies have also shown that asymptomatic children of MP parents with known genetic risk factors have a defect in Miro1 degradation. Together, these data suggest that the presence of a Miro1 defect will serve as an important early diagnostic and prognostic biomarker of PD to accelerate drug discovery, drug development, and clinical trials.

“We are grateful and proud to have the continued support of the Michael J. Fox Foundation to further develop AcureX’s biomarker for Parkinson’s disease,” said William D. Shrader, Ph.D., co-founder and CEO/CSO. from AcureX Therapeutics. “MJFF supports AcureX therapeutic programs, and their support of this biomarker will enable longitudinal studies to better understand disease progression and enable the identification and treatment of patients with PD as early as possible, greatly increasing the odds that therapies improve the quality of life of patients.”

Therapies that slow the progression of Parkinson’s disease will benefit significantly from the presence of a clinical biomarker to monitor target engagement and disease progression to guide drug development and reduce clinical trial risk. . “While we support therapeutic development – including AcureX – towards new treatments and cures for Parkinson’s disease, we are also looking for essential tools to select trial participants and to understand therapeutic impact quickly and objectively. Miro1 is a promising drug discovery tool and biomarker candidate, and results from this project to measure this pathway could accelerate new treatments and improve patient care,” said Brian Fiske, PhD, Scientific Director of MJFF.

About AcureX Therapeutics

AcureX Therapeutics’ mission is to stop neurodegenerative diseases caused by impaired mitophagy, starting with Parkinson’s disease. AcureX plans to have one or more of its late preclinical therapeutic candidates for Parkinson’s disease in human trials in 2023, followed by candidates for other neurodegenerative diseases. AcureX’s innovative approach and founding intellectual property are based on recent discoveries made by the company’s inventor and co-founder, Xinnan Wang MD, Ph.D. AcureX has built a unique target discovery platform and of drugs to accelerate drug development and reduce the risk of clinical trials with an exclusive license to the founding intellectual property. The AcureX team is led by seasoned scientists with a proven track record in CNS drug development and serial life science entrepreneurs. For more information, please visit https://www.acurex.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220427005093/en/

contacts

Ashley Gonzalez, Ph.D.
[email protected]